Pulmonary fibrosis (PF) organizations and healthcare providers are lauding the update of the Official ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmonary Fibrosis, which was last updated in 2011.
As treatments and research into idiopathic pulmonary fibrosis (IPF) advance rapidly, guidelines for treatment of the disease must also be advanced. That is why pulmonary fibrosis (PF) organizations and healthcare providers are lauding the update of the Official ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmonary Fibrosis, which was last updated in 2011.
The updated Guideline, developed by a multidisciplinary panel from the American Thoracic Society, the European Respiratory Society, the Japanese Respiratory Society and the Latin American Thoracic Association, provides an evidence-based rationale for specific treatments for patients with IPF.
Cosgrove“The community is coming together and recognizing the rapid evolution of information and, rather than relying on just expert opinion, the exciting aspect is that we have guidelines that are evidence-based,” said Gregory Cosgrove, MD, chief medical officer of the Pulmonary Fibrosis Foundation (PFF). “As researchers and clinicians, we can validate the information we have based on robust scientific information, and identify areas in which we need more information.”
For the first time, a patient with IPF was included in the panel as they revised the Guideline. “That is a really important step forward. The insight that patients have…is dramatically different than that of researchers and clinicians,” Cosgrove said. “While we hope we understand, we are not placed in the same context they are. It is a much more well-rounded approach to the guide recommendations.”
Among the top additions to the IPF guidelines are:
Meanwhile, the panel deferred recommendations on anti-pulmonary hypertension therapy in IPF – as well as a discussion on single versus bilateral lung transplantation – until the next update.